Ignite Creation Date:
2024-05-06 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05723432
Status:
RECRUITING
Last Update Posted:
2023-04-27
First Post:
2023-02-03
Brief Title:
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
Sponsor:
Shanghai Kanda Biotechnology Co Ltd
Organization:
Shanghai Kanda Biotechnology Co Ltd
Study Overview
Official Title:
A Study to Evaluate the Safety Tolerability Pharmacokinetics and Initial Efficacy of KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1b2 open label study to evaluate the safety tolerability pharmacokinetics and initial efficacy of KD6001 in combination with toripalimab in patients with advanced melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None